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Abstract.
Src kinase activity is regulated by the interaction of SH3 domain with protein sequences that are
rich in proline residues. Identification of more potent SH3 domain binding ligands that can
regulate Src kinase activity is a subject of major interest. Conformationally constrained peptides
have been previously used for improving the binding potency of the Src SH2 domain binding
peptide ligands and peptide substrates of the substrate-binding site of Src. A series of peptide
analogues of Ac-VSLARRPLPPLP (1, Ac-VSL-12, Kd = 0.34 µM) were synthesized by
introducing conformational constraints to improve the binding affinity towards the Src SH3
domain. Peptides synthesized through cyclization between N-terminal to C-terminal
[VSLARRPLPPLP] or N-terminal to side chain flanking residues (i.e., [βAVS]LARRPLPPLP
and [VSLE]RRPLPPLP) exhibited at least 6.4-fold less binding affinity (Kd = 2.19-4.85 µM)
when compared to 1. The data suggest upon N-terminal cyclization with C-terminal or flanking
residues, the interactions of the amino acids in the core RPLPPLP reduce significantly with the
residues within the Src SH3 domain. Conformationally constrained peptide V[SLARRPLPPLP]
(5) was synthesized through cyclization of C-terminal to the serine side chain and displayed a
comparable binding affinity (Kd = 0.35 µM) towards the Src SH3 domain versus that of 1. Thus,
this template may be used to optimize and generate more potent analogues with higher stability.
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1. Introduction
Protein tyrosine kinases (PTKs) catalyze the phosphorylation of specific tyrosine residues
in proteins. Src, a member of nonreceptor tyrosine kinases, is involved in many cellular signaling
pathways. Src contributes significantly in growth, differentiation, proliferation, development, and
motility of many normal cell types [1]. Elevated levels of Src kinase activity are found in
different cancer cells [2]. Thus, control or inhibition the Src kinase activity through chemical
intervention has become a subject of major interest in drug discovery.
Src kinase contains an N-terminal unique domain that constitutes the Src homology
(SH)4, followed by SH3 and SH2 regulatory domains, a kinase (catalytic) domain, and a Cterminal tail which includes a critical tyrosine residue (Tyr527). SH2 and SH3 regulatory
domains mediate protein–protein interactions in cellular signaling cascades [3]. Specificity of
interacting proteins and peptides with Src is determined by the chemical properties of the module
binding surface of the Src SH3 and SH2 domains, which determines a preference for a common
sequence with a range of variability. SH3 domains consist of approximately 60 amino acids and
bind specifically to protein sequences that are rich in proline residues [4], whereas SH2 domains
bind to protein sequences containing a phosphotyrosine residue [5].
The phosphorylation of the Tyr527 in Src by another PTK, Csk, leads to intramolecular
binding of the SH2 domain to the C-terminal tail and inactivation of the enzyme (closed state)
[4,6]. The Src SH3 domain stabilizes this state by interacting with the linker that connects the
SH2 domain to the catalytic domain of the kinase. Src becomes active by autophosporylation of
Tyr416 residue on the catalytic domain (open state) [7].
Src uses the SH3 domain to recruit numerous proteins which contain a polyproline motif
such as Sam 68 [8], STAT3 [9], and p130cas [10,11]. A Src SH3 domain binding ligand can
block the protein–protein interactions between Src and other proteins involved in signal
transduction pathways.
Two classes of the Src SH3 binding ligands have been found that bind in opposite
orientation. Classes I and II contain the consensus sequences of RXLPPXP and XPPLPXR,
respectively [12]. The Src SH3 domain has a highly mobile and flexible region called RT loop
containing arginine (R) and threonine (T) residues. RT loop is involved in interacting with the
Src SH3 domain binding ligands. The binding capacity of both classes correlates on the
positively-charged Arg residue of the ligands interacting with a negatively-charged residue in the
RT loop of the Src SH3 domain. Classes I and II bind to the SH3 domain with the N-terminus or
C-terminus of the ligand towards the RT loop, respectively.
Screening of the SH3 domain with c-DNA libraries, phage display, and biased peptide
libraries has revealed a minimum recognition sequence, PLPPLP, for binding to the Src SH3
domain. Rickles et al. used biased phage display libraries to identify sequence RPLPPLP as the
Src SH3 domain binding ligand with the Kd value of 17.7 µM [13]. Addition of 5 more residues
(VSLAR) flanking to the N-terminal of core ligand RPLPPLP generated peptide
V1S2L3A4R5R6P7L8P9P10L11P12 (VSL-12; Kd = 0.45 µM) with an improved binding affinity of
39-fold versus the core ligand [14]. The structural complex of the ligand and the Src SH3 domain
using NMR showed multiple interactions between the peptide residues in the core region and the
Src SH3 domain [14].
Ferguson et al. showed a bivalent ligand strategy to increase binding between SEM-5
SH3 domain and its natural ligand. A conjugate of PPPVPPR and a cyclic peptide of 6 amino
acid (formed by disulfide bonds between two cysteine residues) improved the binding affinity to
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SH3 domain by 1000-fold as compared to natural ligand [15]. Cyclization strategy has been
commonly used in developing diagnostic and therapeutic peptidic and peptidomimetic agents
[16-19]. Since peptides generally adopt highly flexible conformations in solution, a cyclization
approach is used to reduce the conformational freedom of the molecules and improving binding
affinity of specific conformation. Conformationally constrained structures become usually more
selective in their affinity towards specific receptors and more stable towards proteases. In
addition, cyclization often results in higher receptor binding affinity possibly by reducing
unfavorable entropic effects [20].
We previously designed conformationally constrained peptides for improving the binding
potency of SH2 domain binding peptide ligands [21] and peptide substrates of the substratebinding site of Src [22], demonstrating significantly higher binding affinity by cyclized peptides
compared to the corresponding linear analogues. Herein, we investigated to determine whether
the cyclization of the sequence in VSL-12 can enhance the binding affinity of the ligand to the
SH3 domain. Three cyclization strategies, head to tail, C-terminal to side chain, and N-terminal
to side chain, were used to synthesize conformationally constrained peptides (Fig. 1).
“Please insert Figure 1 here.”
2. Materials and Methods
2.1. Abbreviations
Symbols and abbreviations for amino acids and peptides are in accord with the recommendations
of the IUPAC-IUB Commission on Nomenclature (J. Biol. Chem. 1972, 247, 977). Other
abbreviations used are: AcOH, acetic acid; Boc, tert-butyloxycarbonyl; tBu, tert-butyl; DIC,
N,N′-diisopropylethylcarbodiimide; DIPEA, N,N-diisopropylethylamine; Dmab, 4-[[1-(4,4dimethyl-2,6-dioxocyclohexylidene)-3-methylbutyl]amino]phenyl]methyl] ester); Flu, 5(6)carboxyfluorescein; Fmoc, N-(9-fluorenyl)methoxycarbonyl; HBTU, 2-(1H-benzotriazole-1-yl)1,1,3,3-tetramethyluronium hexafluorophosphate); HOAt, 1-hydroxy-7-azabenzotriazole; HOBt,
1-hydroxybenzotriazole; Mtt, 4-methyltrityl; NMM, N-methylmorpholine; Pbf, (2,2,4,6,7pentamethyldihydrobenzofuran-5-sulfonyl);
2-PhiPr,
2-phenylisopropyl;
PyAOP,
7azabenzotriazol-1-yloxy-tripyrrolidinophosphonium hexafluorophosphate; SELDI-TOF, surfaceenhanced laser desorption/ionization time-of-flight; tBu, tert-butyl; trt, trityl; TFA,
trifluoroacetic acid; TIS, triisopropylsilane. .
2.2. Materials
All reagents used for bacterial culture and protein expression were purchased from Fisher
Scientific. Glutathione S transferase (GST) was purchased from Sigma-Aldrich Chemical Co
(Milwaukee, WI). All the reagents for peptide synthesis were purchased from the Novabiochem.
Fmoc-amino acids, H-Pro-2-chlorotrityl chloride resin, coupling reagents, and Fmoc-amino acid
building blocks were purchased from Novabiochem. Other chemicals and reagents were
purchased from Sigma-Aldrich Chemical Co. (Milwaukee, WI).
2.3. General
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All reactions were carried out in Bio-Rad polypropylene columns by shaking and mixing
using a Glass Col small tube rotator in dry conditions or on a PS3 automated peptide synthesizer
(Rainin Instrument Co., Inc.) at room temperature unless otherwise stated. In general, all
peptides were synthesized by the solid-phase synthesis strategy employing Fmoc-based
chemistry and Fmoc-L-amino acid building blocks. HBTU and DIPEA in DMF were used as
coupling and activating reagents, respectively. Fmoc-deprotection at each step was carried out in
the presence of piperidine in DMF two times (20% v/v, 10x volume as compared with resin)
followed by washing with DMF. Final cleavage of the peptides from the solid support was
achieved by using reagent R (TFA/thioanisole/1,2-ethanedithiol/anisole 90:5:3:2 v/v/v/v, volume
5x compared to dried resin) for 2 h. Crude peptides were precipitated by addition of cold diethyl
ether (Et2O), separated, washed by centrifugation (washed with diethyl ether, 3 × 50 mL and
centrifuged at 4000 rpm for 5 min), and were purified by preparative reverse-phase HPLC
(Shimadzu LC-8A preparative liquid chromatograph) on a Phenomenex-Gemini C18 column (10
µm, 250 × 21.2 mm). The peptides were separated by eluting the crude peptide at 12.0 mL/min
using a gradient of 5-65% acetonitrile (0.1% TFA) and water (0.1% TFA) over 60 min, and then,
they were lyophilized. Chromatograms were recorded at 220 nm using a UV detector. The purity
of final products (>95%) was confirmed by HPLC. The chemical structures of compounds were
determined by a SELDI-TOF mass spectrometer on a Ciphergen protein chip instrument using αcyano-4-hydroxycinnamic as a matrix. Details of procedures are presented below. All of the
amino acids in Ac-V1S2L3A4R5R6P7L8P9P10L11P12 (1) were numbered on the basis of their
positions relative to the N-terminal valine residue (V1).

2.3.1. Peptide Synthesis
2.3.1.1. Ac-V1S2L3A4R5R6P7L8P9P10L11P12 (Ac-VSL-12, 1) and FluoresceinVSLARRPLPPLP (2, Flu-VSL-12). H-Pro-2-chlorotrityl chloride resin (11, 0.91 g, 0.40 mmol,
0.44 mmol/g) was swollen under dry nitrogen using anhydrous DMF for about 15 min. The
excess of the solvent was filtered off. The swelling and filtration steps were repeated for 2 more
times before the coupling reactions. Fmoc-Leu-OH (1.47 g, 4.16 mmol) was coupled to the Nterminal of proline-trityl resin using HBTU (1.52 g, 4.0 mmol) and DIPEA (1.45 mL, 8.8 mmol)
in DMF (5 mL) by mixing for 1.5 h. After the coupling was completed (confirmed by Kaiser
test), the reaction solution was filtered off and the resin was collected by filtration and washed
with DMF (7 × 25 mL), followed by Fmoc-deprotection using piperidine in DMF (20% v/v, 25
mL, 2 times, 5 min and 10 min). The resin was washed with DMF (7 × 25 mL). The subsequent
amino acids, Fmoc-Pro-OH, Fmoc-Pro-OH, Fmoc-Leu-OH, Fmoc-Pro-OH, Fmoc-Arg(Pbf)-OH,
Fmoc-Arg(Pbf)-OH, Fmoc-Ala-OH, Fmoc-Leu-OH, Fmoc-Ser(OtBu)-OH, and Fmoc-Val-OH,
respectively, were coupled in a similar manner. Fmoc-deprotection at N-terminal was carried out
in the presence of piperidine in DMF (20% v/v, 25 mL, 2 × 10 min) to afford 12. The resin was
collected by filtration and washed with DMF (10 × 25 mL). Resin 12 was divided into two
portions, each with 0.2 mmol scale: (1) To the first portion of the resin (0.2 mmol) was added
Ac2O (945 µL, 10 mmol) and DIPEA (1.74 mL, 10.6 mmol) in DMF (6 mL). The mixture was
shaken at room temperature for 45 min. (2) The second portion of resin 12 was labeled with
carboxyfluoresceine at N-terminal. 5(6)-Carboxyfluorescein (0.38 g, 1 mmol) was preactivated
with PyAOP (0.52 g, 1 mmol) and DIPEA (0.35 mL, 2.1 mmol) in DCM/DMF (1:9 v/v, 5 mL)
for 10 min and was added to the second portion of resin 12. The mixture was shaken at room
temperature for 3.5 h. The completion of the coupling was monitored by Kaiser test. The excess
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of the reagents were washed with DMF (10 × 25 mL). Both portions were washed with DMF,
DCM, DMF-MeOH, and MeOH, respectively (each with 2 × 25 mL) to remove the remaining of
reagents and impurities, The resins were dried in vacuum for 24 h. Freshly prepared cleavage
cocktail, reagent R, TFA/thioanisole/1,2-ethanedithiol/anisole (90:5:3:2 v/v/v/v, 10 mL), was
added to the resins. The mixtures were shaken at room temperature for 2 h. The resins were
collected by filtration and washed with another 2 mL of cleavage cocktail. Combined filtrates
were evaporated to a minimum volume under dry nitrogen. After precipitation in Et2O, the crude
peptides were lyophilized and purified by using a semi-preparative reverse-phase HPLC. AcVSL-12 (1): SELLDI-TOF (m/z) [C63H108N18O15]: calcd., 1356.82; found 1357.79, [M + H]+,
1380.69 [M + Na]+ . Flu-VSL12 (2): SELDI-TOF (m/z) [C82H118N18O20]: calcd., 1674.88; found,
1675.82 [M + H]+, 1697.87 [M + Na]+.
2.3.1.2. [VSLARRPLPPLP] (3, head to tail cyclization). The linear peptide was assembled on
the H-Pro-2-chlorotrityl chloride resin (11, 0.44 mmol/g) in 0.41 mmol scale as described above.
After the final deprotection of the N-terminal Fmoc group, the protected peptide was cleaved
from trityl resin 12 in the presence of the cleavage cocktail AcOH/TFE/DCM (1:2:7 v/v/v, 40
mL) for 1 h at room temperature to yield 13. The resin was collected by filtration and washed
with TFE/DCM (2:8 v/v, 2 × 10 mL). The combined filtrates were evaporated in vacuum. To the
residue was added hexane (2 × 25 mL) to remove the acetic acid from the mixture. The crude
protected peptide was dried in vacuum overnight. Examining a small portion of the crude
showed a major peak of the protected peptide by the HPLC. Thus, the crude was used directly
for the cyclization. The dried crude linear protected peptide was dissolved in the DMF/DCM (5:1
v/v, 60 mL). HOAt (223 mg, 1.64 mmol, 4 equiv) and DIC (290 µL, 1.86 mmol, 4.5 equiv.) were
added to the mixture and the solution was stirred for 4 h. After completion of the cyclization, as
shown by the SELDI-TOF, the solvents were removed under reduced pressure on a rotary
evaporator. The crude cyclic protected peptide was dried overnight in vacuum before the final
cleavage. Freshly prepared cleavage cocktail, reagent R, TFA/thioanisole/1,2ethanedithiol/anisole (90:5:3:2 v/v/v/v, 10 mL) was added to dried the cyclic protected peptide.
The mixture was stirred at room temperature for 2 h. The cleavage cocktail was concentrated to a
minimum volume under reduced pressure by a rotary evaporator. After precipitation of crude
peptide in cold Et2O and centrifugation, the crude peptide was lyophilized and purified by using
a semi-preparative reverse-phase HPLC. SELLDI-TOF (m/z) [C61H104N18O13]: calcd., 1296.80;
found, 1297.91 [M + H ]+, 1320.12 [M + Na]+, 1336.01 [M + K]+.
2.3.1.3. Ac-VSAcLARRPLPPLP (4). The linear peptide was assembled on the H-Pro-2chlorotrityl chloride resin (11, 0.45 g, 0.20 mmol, 0.44 mmol/g) on a PS3 automated peptide
synthesizer. HBTU (4 equiv) and NMM (0.40 M) in DMF were used as coupling and activating
reagents. Piperidine in DMF (20% v/v) was used as the deprotecting reagent. The sequence was
assembled using double coupling with Fmoc-Amino Acid-OH building blocks (4 equiv.) as
compared to the resin. The building block used in the synthesis were Fmoc-Leu-OH, Fmoc-ProOH, Fmoc-Pro-OH, Fmoc-Leu-OH, Fmoc-Pro-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Arg(Pbf)-OH,
Fmoc-Ala-OH, Fmoc-Leu-OH, Fmoc-Ser(OTrt)-OH, and Fmoc-Val-OH, respectively.
Deprotection of the Fmoc group at N-terminal of the sequence with piperidine in DMF (20% v/v)
afforded 14. A small portion of the resin was cleaved. The crude was used for confirming the
molecular weight by SELDI-TOF indicating the presence of the linear sequence. The resinattached peptide was mixed with the cleavage cocktail (TFA/DCM/TIS, 1:94:5 v/v/v) (4 ×15
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mL, 10 min.) under mild conditions. The resin was collected by filtration and washed with dry
DCM (5 × 25 mL). Collected combined filtrates were evaporated under reduced pressure.
Partially protected peptide was dried in vacuum and was treated with Ac2O (945 µL, 10 mmol)
in DMF (6 mL) in the presence of DIPEA (1.74 mL, 10.6 mmol) at room temperature for 30 min.
The solvents were removed under reduced pressure on a rotary evaporator and the crude
protected peptide was dried overnight before the final cleavage. Freshly prepared cleavage
cocktail, TFA/thioanisole/1,2-ethanedithiol/anisole (90:5:3:2 v/v/v/v, 10 mL) was added to the
mixture and the solution was stirred at the room temperature for 2 h. The excess of the solvents
were removed under reduced pressure using a rotary evaporator. After precipitation of the crude
peptide in cold Et2O and centrifugation, the crude peptide was lyophilized and purified by using
a semi-preparative reverse-phase HPLC. SELLDI-TOF (m/z) [C61H104N18O13]: calcd., 1367.84;
found, 1368.81 [M + H]+, 1391.03 [M + Na]+, 1406.72 [M + K]+.
2.3.1.4. V[SLARRPLPPLP] (5, C-terminal to side chain cyclization). The linear peptide was
assembled on H-Pro-2-chlorotrityl chloride resin (11, 0.91 g, 0.40 mmol, 0.44 mmol/g) as
described above on a PS3 automated peptide synthesizer. Boc-Val-OH was used in place of the
regular Fmoc-Val-OH at position 1. After assembling the linear peptide chain, using building
blocks Fmoc-Leu-OH, Fmoc-Pro-OH, Fmoc-Pro-OH, Fmoc-Leu-OH, Fmoc-Pro-OH, FmocArg(Pbf)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Ala-OH, Fmoc-Leu-OH, Fmoc-Ser(OTrt)-OH, and
Boc-Val-OH, a small portion of the resin was cleaved, and the molecular weight was confirmed
by SELDI-TOF. The resin-attached peptide was mixed with the cleavage cocktail,
TFA/DCM/TIS (1:94:5 v/v/v, 5 × 25 mL, 10 min.) to deprotect the trityl group from the side
chain of the serine and to cleave the partially protected peptide from the resin to afford 15. The
resin was collected by filtration and was washed with dry DCM (5 × 25 mL). The combined
filtrates were evaporated under reduced pressure. The partially protected crude peptide was dried
in vacuum overnight. A small portion of the crude showed a major peak of protected peptide by
HPLC. Thus, the crude was used directly for the cyclization. The crude peptide was dried and
dissolved in DMF/DCM (5:1 v/v, 60 mL). HOBt (109 mg, 0.8 mmol), HBTU (303 mg, 0.8
mmol), DIC (125 µL, 0.8 mmol), and DIPEA (697 µL, 4.2 mmol) were added to the solution.
The mixture was stirred slowly at room temperature for 8 h. After completion of the cyclization,
as shown by SELDI-TOF, the solvents were removed on a rotary evaporator. The crude cyclic
protected peptide was dried overnight in vacuum before the final cleavage. Freshly prepared
cleavage cocktail, reagent R, TFA/thioanisole/1,2-ethanedithiol/anisole (90:5:3:2 v/v/v/v, 10
mL), was added to dried cyclic protected peptide. The mixture was stirred at room temperature
for 2 h. After 2 h, the cleavage cocktail was concentrated under reduced pressure to minimum
volume by a rotary evaporator. After precipitation of the crude peptide in cold Et2O and
centrifugation, the crude peptide was lyophilized and purified by using a semi-preparative
reverse-phase HPLC. SELDI-TOF (m/z) [C61H104N18O13]: calcd., 1296.80; found 1297.92 [M +
H]+, 1320.13 [M + Na]+, 1336.02 [M + K]+.
2.3.1.5. [βAVS]LARRPLPPLP (6, N-terminal to side chain cyclization). The linear peptide
was synthesized on a PS3 automatic peptide synthesizer as described above using Fmoc-ProWang resin (16, 0.35 mmol, 0.51 mmol/g). HBTU (4 equiv) and NMM (0.37 M) in DMF were
used as coupling and activating reagents. Piperidine in DMF (20% v/v) was used as the
deprotecting reagent. The sequence was assembled using double coupling with Fmoc-Amino
Acid-OH building blocks (4 equiv.) as compared to the resin. The building block used in the
synthesis were Fmoc-Leu-OH, Fmoc-Pro-OH, Fmoc-Pro-OH, Fmoc-Leu-OH, Fmoc-Pro-OH,
7

Fmoc-Arg(Pbf)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Ala-OH, Fmoc-Leu-OH, Fmoc-Ser(OTrt)-OH,
Fmoc-Val-OH, and Fmoc-β-Ala-OH, respectively. After deprotection of the Fmoc group at the
end of N-terminal of the sequence with piperidine in DMF (20% v/v), a small portion of the resin
was cleaved and the molecular weight of the peptide was confirmed by SELDI-TOF. The trityl
group from the side chain of the serine was removed under mild conditions (TFA/DCM/TIS,
1:94:5 v/v/v, 30 mL, 4 × 10 min.) to yield 17. The resin was collected by filtration and was
washed with dry DCM (5 × 50 mL). The resin was dried in vacuum for 30 min. To the resinattached peptide was added, DMF/DCM (60 mL, 5:1 v/v), HOAt (190.5 mg, 1.4 mmol, 4 equiv),
and DIC (245 µL, 1.57 mmol, 4.5 equiv) and the mixture was shaken at room temperature for 8
h. The completion of cyclization was confirmed by Kaiser test as well as by SELDI-TOF. The
resin was collected by filtration. After washing the resin by DMF, DCM, and MeOH,
respectively (each 5 × 30 mL), the resin was dried in vacuum for 24 h. Freshly prepared cleavage
cocktail, reagent R, TFA/thioanisole/1,2-ethanedithiol/anisole (90:5:3:2 v/v/v/v, 12 mL), was
added to dried resin-attached peptide. The mixture was shaken at room temperature for 2 h. After
filtration, the filtrate was concentrated to a minimum volume under reduced pressure by a rotary
evaporator. After precipitation of the crude peptide in cold Et2O and centrifugation, the crude
peptide was lyophilized and purified by using semi-preparative reverse-phase HPLC. SELDITOF (m/z) [C61H104N18O13]: calcd., 1367.84; found, 1368.81 [M + H]+, 1391.03 [M + Na]+,
1406.71 [M + K]+
2.3.1.6. Ac-VSLKAcRRPLPPLP (7). The linear peptide was assembled on the H-Pro-2chlorotrityl chloride resin (11, 0.45 g, 0.20 mmol, 0.44 mmol/g) as described above on a PS3
automated peptide synthesizer. Fmoc-Lys (Mtt)-OH was used in place of Fmoc-Ala-OH at
position 4. Assembling of the linear peptide chain was carried out using building blocks, FmocLeu-OH, Fmoc-Pro-OH, Fmoc-Pro-OH, Fmoc-Leu-OH, Fmoc-Pro-OH, Fmoc-Arg(Pbf)-OH,
Fmoc-Arg(Pbf)-OH, Fmoc-Lys (Mtt)-OH, Fmoc-Leu-OH, Fmoc-Ser(OtBu)-OH, and Fmoc-ValOH, respectively. After deprotection of the Fmoc group at the end of N-terminal of the sequence,
a small portion of resin 18 was cleaved. The crude was monitored with SELDI-TOF confirming
the molecular weight of the linear sequence. Resin 18 was mixed with the cleavage cocktail,
(TFA/DCM/TIS) (2:93:5 v/v/v, 15 mL, 5 × 15 min.), to deprotect the Mtt group from the side
chain of the lysine and to cleave the partially protected peptide from the resin. The resin was
collected by filtration and was washed with dry DCM (5 × 25 mL). Collected combined filtrates
were evaporated in vacuum. The partially protected peptide was dried in vacuum and was treated
with Ac2O (945 µL, 10 mmol) and DIPEA (1.74 mL, 10 mmol) in DMF (6 mL). The mixture
was shaken at room temperature for 30 min. The solvents were removed under reduced pressure
on a rotary evaporator and the crude was dried overnight before the final cleavage. Freshly
prepared cleavage cocktail, TFA/thioanisole/1,2-ethanedithiol/anisole (90:5:3:2 v/v/v/v, 10 mL),
was added to the crude and the mixture was stirred at the room temperature for 2 h. The excess
of the solvent was removed using a rotary evaporator. After precipitation of the crude peptide in
cold Et2O, and centrifugation, the crude peptide was lyophilized and purified by using a semipreparative reverse-phase HPLC. SELDI-TOF (m/z) for [C68H117N19O16]: calcd, 1455.89; found,
1456.61 [M + H]+, 1478.90 [M + Na]+, 1494.81 [M + K]+.
2.3.1.7. VSL[KRRPLPPLP] (8, C-terminal to side chain cyclization). The linear peptide was
assembled on H-Pro-2-chlorotrityl chloride resin (11, 0.91 g, 0.40 mmol, 0.44 mmol/g) as
described above on a PS3 automated peptide synthesizer. Fmoc-Lys(Mtt)-OH and Boc-Val-OH
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were used in place of Fmoc-Ala-OH and Fmoc-Val-OH at positions 1 and 4, respectively. The
peptide assembly was carried out using building blocks Fmoc-Leu-OH, Fmoc-Pro-OH, FmocPro-OH, Fmoc-Leu-OH, Fmoc-Pro-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Lys
(Mtt)-OH, Fmoc-Leu-OH, Fmoc-Ser(OtBu)-OH, and Boc-Val-OH to yield 19. After completion
of the sequence, a small portion of the resin was cleaved. The crude showed the molecular
weight of the linear sequence using SELDI-TOF. Resin 19 was mixed with the cleavage cocktail,
TFA/DCM/TIS (2:93:5 v/v/v, 15 mL, 5 × 15 min.), to deprotect the Mtt group from the side
chain of the lysine and to cleave the partially protected peptide from the resin to yield 20. The
resin was washed with dry DCM (5 × 25 mL) and collected combined filtrates were evaporated
under reduced pressure. After drying the partial protected crude peptide, the cyclization of the
side chain with the C-terminal was achieved in the solution phase. The crude was dried and
dissolved in DMF/DCM (5:1 v/v, 60 mL). HOAt (223 mg, 1.64 mmol) and DIC (290 µL, 1.86
mmol) were added and the mixture was stirred for 8 h. After completion of the cyclization, as
shown by the SELDI-TOF, the solvents were removed on a rotary evaporator. The crude cyclic
protected peptide was dried overnight before the final cleavage. Freshly prepared cleavage
cocktail reagent R, TFA/thioanisole/1,2-ethanedithiol/anisole (90:5:3:2 v/v/v/v, 10 mL), was
added to dried cyclic protected peptide. The solution was stirred at room temperature for 2 h. The
cleavage cocktail was concentrated to a minimum volume under reduced pressure by using a
rotary evaporator. After precipitation of the crude peptide in cold Et2O, and centrifugation, the
crude peptide was lyophilized and purified by using a semi-preparative reverse-phase HPLC.
SELDI-TOF (m/z) for [C61H104N18O13]: calcd., 1354.70; found, 1356.11 [M +H]+, 1378.31 [M +
Na]+, 1393.70 [M + K]+.
2.3.1.8. VSLERRPLPPLP (9) and [VSLE]RRPLPPLP (10, N-terminal to side chain
cyclization). The linear peptide was assembled on H-Pro-2-chlorotrityl chloride resin (11, 0.91
g, 0.40 mmol, 0.44 mmol/g) as described above on a PS3 automated peptide synthesizer. FmocGlu(ODmab)-OH was used in the place of Fmoc-Ala-OH at position 4. The Fmoc group of the
N-terminal was removed with piperidine (20%) to yield 21. The Dmab group from the side chain
of the glutamic acid was removed using hydrazine hydrate in DMF (2%, 3 × 25 mL) for 10 min
to afford 22. The resin-attached peptide was washed with the excess of the solvents, DMF,
DCM, and DMF, respectively (each 3 × 35 mL) and was dried in vacuum overnight. The resin
was divided into two portions. The first portion was used for the synthesis of the linear peptide
by cleavage using reagent R to yield 9 as described below. The second part of 22 was used for
the cyclization between N-terminal and the COOH group of the side chain of glutamic acid. The
resin was swollen in the dry DMF under nitrogen. The excess of solvent was removed and to the
resin was added DMF/DCM (5:1 v/v, 60 mL), HOAt (112 mg, 0.82 mmol), and DIC (145 µL,
9.3 mmol). The mixture was agitated for 12 h at room temperature. After completion of the
cyclization, as shown by SELDI-TOF by cleavage of a few resin beads, the solvents were
removed by filtration. The resin was washed with excess of solvents, DMF, DCM, and MeOH (3
× 35 mL, each), respectively, and dried in vacuum overnight. Freshly prepared cleavage cocktail,
TFA/thioanisole/1,2-ethanedithiol/anisole (90:5:3:2 v/v/v/v, 10 mL), was added to dried cyclic
and linear peptide resins and the mixture was shaken at room temperature for 2 h. The resins
were collected by filtration and washed with another 2 mL of cleavage cocktail. Combined
filtrates of both peptides were evaporated in separate flask to a minimum volume amount under
dry nitrogen. After precipitation of the crude peptide in cold Et2O, and centrifugation, the crude
peptide was lyophilized and purified by using semi-preparative reverse-phase HPLC. 9: SELDI-
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TOF (m/z) for [C63H108N18O16]: calcd., 1372.82; found, 1374.0 [M + H]+; 1395.91 [M + Na]+.
10: SELDI-TOF (m/z) for [C61H104N18O13]; calcd., 1355.63; found, 1356.64 [M + H]+; 1378.70
[M + Na]+.
2.3.2. SH3 domain protein purification. The Chicken Src SH3 domain was expressed as a
glutathione S-transferase fusion protein in E. coli DH5α cells using the plasmid pGEX-4T1.
Upon sequence verification, a 500 mL culture of cells in LB and ampicillin were grown at 37 ºC
while shaking at 250 rpm. When an OD600 of about 0.6 was achieved, the culture was diluted
with another 500 mL of fresh LB and ampicillin and expression was induced with 400 µM IPTG.
The induction was for 8 h at 250 rpm and 20 ºC. Harvesting of the cells by centrifugation was
followed by freeze-thaw cycle and re-suspension in fresh PBS buffer pH 7.4. The cells were then
sonicated and the lysate was cleared by centrifugation. The lysate was incubated for a period of
one hour with approximately 1 mL glutathione-agarose at 4 ºC. This lysate was then passed
through a column and washed with 40 mL each of PBS, 50 mM Tris-Cl pH 7.4, and 50 mM TrisCl pH 8.0. The elution of purified GST-Src SH3 fusion protein was then carried out with 10 mM
reduced glutathione in 50 mM Tris pH 8.0. All buffers used were chilled and 0.1% βmercaptoethanol was added fresh prior to use. Eluted fractions were qualified and quantified by
Bradford assay and SDS-PAGE, respectively (Fig. 2). These fractions, ranging from 2.25 to 7.50
g/L in concentration, were aliquoted and stored in the elution buffer at -20 ºC
“Please insert Figure 2 here.”
2.3.3. Fluorescence polarization assay
To determine the binding of VSL12 towards the Src SH3 domain, fluorescein-labeled VSL12
was synthesized and purified by HPLC as described above. The fluorescence polarization (FP)
binding assay was carried out as described previously [23]. Flu-VSL12 (120 nM) was kept
constant in the presence of increasing SH3 domain concentration in 50 mM Tris pH 8.0 buffer.
FP was then detected using a PerkinElmer LS55 Luminescence Spectrophotometer at 25 ºC.
Wavelengths utilized were 485 nM for excitation and 530 nM for emission. The net change in FP
as a function of the SH3 domain concentration was fit to the following equation: FP = FPmax ×
[SH3] / (Kd + [SH3]), where FPmax was the maximum polarization value at saturation and Kd was
the dissociation constant of VSL12 binding to Src SH3 domain. Data analysis was carried out
using LabFit software.
The binding of unlabeled Ac-VSL12 (1) to compete against Flu-VSL12 (2) in binding to
the Src SH3 domain was evaluated. The initial competition screening tested the effect of 500 nM
unlabeled derivative on the binding of Flu-VSL12 to the Src SH3 domain. The concentration of
Flu-VSL12 and SH3 domain were 120 nM and 1 µM, respectively. Subsequently, a second
round of screening was carried out with 2 µM unlabeled derivative in the presence of 2 µM of
Src SH3 and 120 nM of Flu-VSL12.
All newly synthesized VSL12 derivatives (3-10) were then fully evaluated in triplicate,
for their binding to the Src SH3. With Flu-VSL12 at 120 nM, VSL12 and SH3 domain were used
at constant concentrations of 1 µM. The peptides were used at concentrations of 0, 0.25, 0.5, 1.0,
2.0, and 4.0 µM. The binding buffer was 50 mM Tris pH = 8.0. The Kd was then determined for
the competing ligand by plotting the FP as a function of the increasing concentration of the
unlabeled derivative and fitting the curve to the equation: FP = A × ([SH3]t × [Probe]t × Kd2)/(Kd1
× Kd2 + Kd1 × [Pept]t + [SH3]t × Kd2), where Kd1 is the dissociation constant of Flu-VSL12, as
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determined above and Kd2 is the dissociation constant of the unlabeled VSL12 derivative. A is a
conversion factor between the concentration of the probe-SH3 complex and the FP value. [SH3]t
and [Probe]t were total SH3 and Flu-VSL12 concentrations. [Pept]t is the total concentration of
unlabeled competing ligand.
3. Results and Discussion
3.1. Chemistry
The presence of proline residue at the carboxy terminus of a peptide during solid-phase
peptide synthesis has been associated with high levels of diketopiperazine formation [24]. Thus,
the synthesis was carried out on a 2-chlorotrityl chloride resin. The bulkiness of the trityl linker
minimized diketopiperazine formation during tripeptide formation.
Scheme 1 shows the synthesis of Ac-VSL12 (Ac-VSLARRPLPPLP, 1), the fluoresceinlabeled VSL12 (Fluorescein-VSLARRPLPPLP, Flu-VSL-12, 2), and the conformationally
constrained peptide (3) resulted from head to tail cyclization. To synthesize compound 1 and its
carboxyfluorescein derivative (2), H-Pro-2-chlorotrityl chloride resin 11 was used and the linear
sequence was assembled on the resin using Fmoc/tBu solid-phase peptide synthesis methodology
(Scheme 1). The Fmoc group at the end of the synthesis was removed by using piperidine (20%
v/v) in DMF to yield 12. Resin-attached peptide 12 was capped by using acetic anhydride in
DMF and underwent cleavage and deprotection to afford 1. Alternatively, resin 12 was
conjugated with the 5(6)-carboxyfluorescein in the presence of PyAOP/HOAt/DMF in DMF,
which after final cleavage and deprotection gave fluorescent-labeled peptide 2. The fluorescent
probe was used for determination of the binding affinity between the Src SH3 domain and
synthesized compounds.
The synthesis of conformationally constrained peptide [VSLARRPLPPLP] (3) by head to
tail cyclization was performed by using resin 12. The cleavage in the presence of
AcOH/TFE/DCM (1:2:7 v/v/v) for 1 h at room temperature afforded the linear protected peptide
13 with free N- and C-terminals. Head to tail cyclization was carried out in the presence of
HOAt/DIC in DMF/DCM. Deprotection with reagent R and purification afforded
conformationally constrained peptide 3 (Scheme 1).
“Please insert Scheme 1 here.”
The synthesis of diacetylated linear peptide Ac-VSAcLARRPLPPLP (4) is depicted in
Scheme 2. Fmoc-Ser(Trt)-OH at position 2 was assembled as the building block on resinattached peptide while synthesizing the sequence of the VSL-12 on H-Pro-2-chlorotrityl resin
(11). The Fmoc group was removed from the N-terminal to yield 14. The deprotection of the
trityl group and cleavage from the resin in the presence of cocktail (TFA/DCM/TIS) (1:94:5
v/v/v) afforded the partially protected peptide. The N-terminal of the peptide and side chain of
serine were capped with acetyl group in the presence of acetic anhydride and DIPEA in DMF at
room temperature to give 4. Because of capped serine residue, 4 cannot be used to perform
cyclization between C-terminal and side chain of serine.
To cyclize the peptide through C-terminal to side chain cyclization, Boc protected valine
(Boc-Val-OH) and Fmoc-Ser(Trt)-OH were used at positions 1 and 2 while assembling the
peptide on resin 11. Thus, no capping step was required before the cyclization. The deprotection
of the serine side chain and cleavage from the resin were achieved by using a cleavage cocktail,
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TFA/DCM/TIS (1:94:5 v/v/v), to yield the partially protected peptide 15, which underwent
cyclization in the presence of HOBt, HBTU, DIC, DIPEA in DMF/DCM (5:1, v/v) at room
temperature for 8 h. After cyclization between C-terminal and side chain of serine, the final
deprotection was achieved by using reagent R to afford compound V[SLARRPLPPLP] (5)
(Scheme 2).
“Please insert Scheme 2 here.”
N-terminal valine to side chain serine cyclization failed when 2-chlorotrityl resin was
used due to simultaneous deprotection of serine side chain and cleavage of partially protected
peptide from the trityl resin in one step. Because of high sensitivity of trityl resin to acid, Fmocpro-Wang resin (16) was used for the synthesis (Scheme 3). After every coupling, a small
amount of resin was cleaved to monitor the progress of the reaction by confirming the molecular
weight of the peptide using SELDI-TOF. The cyclization between N-terminal valine and the side
chain of serine was not successful. β-Alanine was assembled at the N-terminal of linear peptide.
After Fmoc-deprotection, the trityl group from the side chain of serine was deprotected using a
cleavage cocktail, TFA/DCM/TIS (1:94:5 v/v/v), to afford 17. The cyclization between free
amino group of β-alanine and the side chain of serine at position 3 was carried out in the
presence of HOAt, DIC, and DMF/DCM (5:1 v/v) at room temperature for 8 h. The final
cleavage afforded [βAVS]LARRPLPPLP (6).
“Please insert Scheme 3 here.”
The synthesis of diacetylated linear peptide Ac-VSLKAcRRPLPPLP (7) was started using
Fmoc solid-phase synthesis protocol on 2-chlorotrityl resin 11 using Fmoc-Lys(Mtt)-OH in place
of alanine at position 4 (Scheme 4). After the assembly of the peptide, the Fmoc group was
removed from the N-terminal to yield 18. Deprotection of the MTT group followed by the
cleavage of the partially protected peptide from the resin was achieved in the presence of
cleavage cocktail, TFA/DCM/TIS (2:93:5 v/v/v). Capping the peptide with acetic anhydride,
followed by deprotection by Reagent R afforded the diacetylated peptide AcVSLKAcRRPLPPLP (7).
The synthesis of the conformationally constrained peptide VSL[KRRPLPPLP] (8) (Cterminal to side chain cyclization) was carried out using Boc-Val-OH in place of Fmoc-Val-OH
at position 1 to afford 19. The Mtt group from the side chain of lysine was cleaved and the
partially protected peptide was cleaved from the resin in the presence of cleavage cocktail,
TFA/DCM/TIS (2:93:5 v/v/v) to yield 20 (Scheme 4). C-terminal to side chain cyclization was
achieved in the presence of HOAt and DIC in DMF/DCM (5:1 v/v). Final deprotection afforded
the conformationally constrained peptide VSL[KRRPLPPLP] (8).
“Please insert Scheme 4 here.”
The synthesis of linear peptide VSLERRPLPPLP (9) and conformationally constrained
peptide [VSLE]RRPLPPLP (10, N-terminal to side chain cyclization) is shown in Scheme 5. The
linear peptide was assembled on resin 11 by using Fmoc-Glu (ODmab)-OH in the place of
Fmoc-Ala-OH at position 4. Removing the Fmoc group of the N-terminal afforded resin-attached
peptide 21. The Dmab group from the side chain of the glutamic acid was removed using
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hydrazine hydrate in DMF (2%) to yield 22. A portion of resin-attached peptide was cleaved and
deprotected to afford compound 9. Furthermore, another part of resin-attached peptide 22
underwent cyclization between NH2 group of the N-terminal and the side chain COOH group of
glutamic acid residue in the presence of HOAt, DIC, and DMF/DCM (5:1 v/v). The final
cleavage and deprotection afforded peptide 10.
“Please insert Scheme 5 here.”
3.2. Fluorescent Polarization Binding Assay
The binding affinities of the synthesized peptides (2-10) against the Src SH3 domain
were examined and compared with the corresponding linear peptide (1) (Table 1) using a
fluorescence polarization competitive assay [23]. Unlabeled linear probe 1 competed with probe
2 for binding to the Src SH3 domain resulting in the decreased FP values. Ac-VSL-12 (1)
showed a Kd value of 0.34 µM that was consistent with the reported value [14].
VSL-12 contains a core RPLPPLP that forms a helix upon binding with the Src SH3
domain. VSLAR flanking sequence in VSL-12 was selected from a phage library to increase the
binding affinity of the core sequence [14]. There are three major interactions between the core
portion of VSL-12 and the Src SH3 domain (i.e. hydrophobic, electrostatic, and hydrogen
bonding interactions). Both Leu8-Pro9 and Leu11-Pro12 moieties bind to hydrophobic pockets
containing Tyr90, Tyr92, Tyr136, and Trp118 of the Src SH3 domain. Additionally, Arg6 in
RPLPPLP portion forms a salt bridge with Asp99 near the RT loop of the SH3 domain. The
carbonyl of Arg6 in VSL-12 and the indole of NH of Trp118 forms a hydrogen bond. Side chain
NH2 of Asn59 in the SH3 domain make an intermolecular hydrogen bond with the carbonyl of
Pro9 in the ligand. Other intermolecular hydrogen bonding interactions are formed between the
carbonyl of Pro10 in the ligand and the hydroxyl of Tyr136 [14].
The corresponding conformationally constrained peptide 3, synthesized through head to
tail cyclization of VSL-12, showed 10-fold weaker binding affinity (Kd =3.5 µM) when
compared with 1. Decreased binding affinity towards the Src SH3 domain by a non-linear
structure 3 may be due to the loss of some of hydrophobic, hydrogen bonding, and/or
electrostatic interactions between some residues in the constrained peptide and the Src SH3
domain. The folded structure in 3 may not provide appropriate locations for the side chains of
amino acids, Leu-Pro and Arg, in RPLPPLP for maximal interactions with hydrophobic pockets
and negatively-charged Asp99 of the Src SH3 domain.
Diacetylated peptide 4 with a capped OH group of serine residue at position 2 exhibited a
comparable binding affinity (Kd = 0.56 µM) versus that of VSL-12, suggesting that the side chain
of serine may be used for the synthesis of constrained peptides without the significant loss of
binding affinity. Thus, conformationally constrained peptide 5 was synthesized through Cterminal cyclization with the side chain residue of serine at position 2, and showed similar
binding affinity (Kd = 0.35 µM) when compared the corresponding linear peptide 1. These data
suggest that cyclization between serine 2 in flanking residues (VSLAR) and C-terminal can be
tolerated. Flanking residues Leu3, Ala4, and Arg5 of VSL-12 occupy a large pocket surrounded
by Trp118, Tyr131 and RT loop of the Src SH3 domain [14]. The size of the pocket allows the
cyclization with serine 2 in the flanking residues without disturbing the hydrophobic and
electrostatic interactions by core RPLPPLP residues.
On the other hand, N-terminal cyclization with the side chain of serine residue at position
2 in flanking sequence in conformationally constrained peptide 6 decreased binding affinity (Kd
=4.8 µM). These data indicate that use of N-terminal residue in generating conformationally
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constrained peptides as shown in peptides 3 and 6 was counterproductive, possibly due to critical
interaction of N-terminal residue valine 1 with the Src SH3 domain. The flanking sequences
increase binding affinity of the ligands to SH3 domain and in the case of 6 the cyclization
between flanking residues appears to significantly affect the ability of the peptide to bind with
the Src SH3 domain.
The placement of a capped lysine residue at position 4 in peptide 7 in place of alanine
reduced the binding affinity (Kd =2.2 µM). Similarly, the placement of negatively-charged
glutamic acid at position 4 in peptide 9 was not beneficial (Kd =2.7 µM). Flanking residues Ala4
of VSL-12 occupy a pocket surrounded by Trp118, Tyr131 and RT loop of the Src SH3 domain
and replacement of the Ala with a large side chains in 7 and 9 was not tolerated. As expected
cyclization of C-terminal to side chain of lysine residue (K4) in peptide 8 did not improve the
binding affinity (Kd =2.9 µM) possibly due to significant change in the structure for appropriate
interactions with the SH3 domain.
Cyclization of N-terminal to side chain of glutamic acid residue at position 4 (E4) in
peptide 10 improved the binding affinity marginally (Kd = 2.2 µM) when compared to the
corresponding linear peptide 9.
Table 1. The binding affinities of peptides towards the Src SH3 domaina.
Peptide
Sequence
Kdb
VSL-12 (1)
Ac-VSLARRPLPPLP
0.34
[VSLARRPLPPLP]
3.54
3
Ac-VS(Ac)LARRPLPPLP
0.56
4
V[SLARRPLPPLP]
0.35
5
4.85
6
[βAVS]LARRPLPPLP
Ac-VSLK(Ac)RRPLPPLP
2.21
7
VSL[KRRPLPPLP]
2.96
8
VSLERRPLPPLP
2.70
9
[VSLE]RRPLPPLP
2.19
10
a
[Src SH3] = 1 µM, [Flu-VSL12, 2]=120 nM; bIn general mean of three separate determinations
with a standard deviation of less than 5%.
In general, these data provide structure-activity relationships for VSL-12 derivatives. The
optimal binding of VSL-12 with the Src SH3 domain occur through delicate hydrophobic,
electrostatic, and hydrogen bonding interactions of core and flanking residues of the ligand with
specific residues of the protein when the peptide is oriented in an extended form. The Src SH3
domain binding pocket is shallow, thus the design of conformationally constrained peptides for
this regulatory domain remains a challenge as residues in cyclized peptides lose some critical
interactions. These results suggest that N-terminal cyclization reduces the binding affinity
towards the Src SH3 domain compared to linear peptide 1 as shown in conformationally
constrained peptides 3, 6, and 10. Thus, N-terminal valine 1 in VSL-12 cannot be subjected to
strain for generating more potent Src SH3 domain binding ligands. Further optimization of
conformationally constrained peptide 5 or generating other constrained peptides through side
chain to side chain cyclization may result in producing ligands with appropriate orientation and
more optimal binding affinity and stability.
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Figure and Scheme Legends

Fig. 1. The chemical structures of the conformationally constrained and linear peptide analogues
of VSL12 (1-10).

Fig. 2. SDS-PAGE of GST-Src SH3 fusion protein, stained with Coomassie Blue.

Scheme 1. Synthesis of Ac-VSL-12 (1), Flu-VSL-12 (2), and [VSLARRPLPPLP] (3) (head to
tail cyclization). Reagents and reaction conditions: (i) (a) Fmoc solid-phase synthesis: coupling
of Fmoc-Leu-OH, Fmoc-Pro-OH, Fmoc-Pro-OH, Fmoc-Leu-OH, Fmoc-Pro-OH, FmocArg(Pbf)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Ala-OH, Fmoc-Leu-OH, Fmoc-Ser(OtBu)-OH, and
Fmoc-Val-OH, respectively, in the presence of HBTU/DIPEA in DMF with Fmoc-deprotection
(20% v/v Piperidine in DMF) after each coupling; (ii) 20% Piperidine in DMF; (iii) Ac2O,
DIPEA, DMF; (iv) reagent R, 2 h; (v) 5(6)-carboxyfluorescein, PyAOP, DIPEA, DCM/DMF(1:9
v/v), 3.5 h; (vi) AcOH/TFE/DCM (1:2:7 v/v/v), 1h and then TFE/DCM (2:8 v/v); (vii) HOAt,
DIC, DMF/DCM (5:1 v/v), 2 h.

Scheme 2. Synthesis of Ac-VS(Ac)LARRPLPPLP (4) and V[SLARRPLPPLP] (5, C-terminal to
side chain cyclization). Reagents and reaction conditions: (i) Fmoc solid-phase synthesis:
coupling of Fmoc-Leu-OH, Fmoc-Pro-OH, Fmoc-Pro-OH, Fmoc-Leu-OH, Fmoc-Pro-OH,
Fmoc-Arg(Pbf)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Ala-OH, Fmoc-Leu-OH, Fmoc-Ser(OTrt)-OH,
and Fmoc-Val-OH, respectively, in the presence of HBTU/DIPEA in DMF with Fmocdeprotection (20% Piperidine in DMF) after each coupling; (ii) 20% Piperidine in DMF; (iii)
(TFA/DCM/TIS) (1:94:5 v/v/v), (iv) Ac2O DIPEA, DMF; (v) Reagent R, 2 h; (vi) Fmoc solid-
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phase synthesis: coupling of Fmoc-Leu-OH, Fmoc-Pro-OH, Fmoc-Pro-OH, Fmoc-Leu-OH,
Fmoc-Pro-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Ala-OH, Fmoc-Leu-OH, FmocSer(OTrt)-OH, and Boc-Val-OH, respectively, in the presence of HBTU/DIPEA in DMF with
Fmoc-deprotection (20% Piperidine in DMF) after each coupling; (vii) TFA/DCM/TIS (1:94:5
v/v/v), (viii) HOBt, HBTU, DIC, DIPEA in DMF/DCM (5:1 v/v), 8 h.

Scheme 3. Synthesis of [βAVS]LARRPLPPLP (6) (N-terminal to side chain cyclization).
Reagents and reaction conditions: (i) Fmoc solid-phase synthesis: coupling of Fmoc-Leu-OH,
Fmoc-Pro-OH, Fmoc-Pro-OH, Fmoc-Leu-OH, Fmoc-Pro-OH, Fmoc-Arg(Pbf)-OH, FmocArg(Pbf)-OH, Fmoc-Ala-OH, Fmoc-Leu-OH, Fmoc-Ser(Trt)-OH, Fmoc-Val-OH, and Fmoc-βAla-OH, respectively, in the presence of HBTU/DIPEA in DMF with Fmoc-deprotection (20%
piperidine in DMF) after each coupling; (ii) 20% Piperidine in DMF; (iii) TFA/DCM/TIS
(1:94:5 v/v/v); (iv) HOAt (4 equiv), DIC (4.5 equiv.), DMF/DCM (5:1 v/v), 8 h; (v) Reagent R.

Scheme 4. Synthesis of Ac-VSLKAcRRPLPPLP (7) and VSL[KRRPLPPLP] 8 (C-terminal to
side chain cyclization). Reagents and reaction conditions: (i) Fmoc solid-phase synthesis: FmocLeu-OH, Fmoc-Pro-OH, Fmoc-Pro-OH, Fmoc-Leu-OH, Fmoc-Pro-OH, Fmoc-Arg(Pbf)-OH,
Fmoc-Arg(Pbf)-OH, Fmoc-Lys (Mtt)-OH, Fmoc-Leu-OH, Fmoc-Ser(OtBu)-OH, and Fmoc-ValOH, respectively, in the presence of HBTU/DIPEA in DMF with Fmoc-deprotection (20%
Piperidine in DMF) after each coupling; (ii) 20% Piperidine in DMF; (iii) TFA/DCM/TIS
(2:93:5 v/v/v); (iv) Ac2O, DIPEA, DMF; (v) Reagent R, 2 h; (vi) Fmoc solid-phase synthesis:
Fmoc-Leu-OH, Fmoc-Pro-OH, Fmoc-Pro-OH, Fmoc-Leu-OH, Fmoc-Pro-OH, Fmoc-Arg(Pbf)OH, Fmoc-Arg(Pbf)-OH, Fmoc-Lys (Mtt)-OH, Fmoc-Leu-OH, Fmoc-Ser(OtBu)-OH, and Boc-
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Val-OH, respectively, in the presence of HBTU/DIPEA in DMF with Fmoc-deprotection (20%
Piperidine in DMF) after each coupling; (vii) HOAt, DIC, DMF/DCM (5:1 v/v), 8 h.

Scheme 5. Synthesis of VSLERRPLPPLP (9) and [VSLE]RRPLPPLP (10, N-terminal to side
chain cyclization): (i) (a) Fmoc solid-phase synthesis: coupling of Fmoc-Leu-OH, Fmoc-ProOH, Fmoc-Pro-OH, Fmoc-Leu-OH, Fmoc-Pro-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Arg(Pbf)-OH,
Fmoc-Glu(ODmab)-OH, Fmoc-Leu-OH, Fmoc-Ser(OtBu)-OH, and Fmoc-Val-OH, respectively,
in the presence of HBTU/DIPEA in DMF with Fmoc-deprotection (20% Piperidine in DMF)
after each coupling; (ii) 20% Piperidine in DMF; (iii) hydrazine hydrate in DMF (2%, 3 × 25
mL), 10 min; (iv) HOAt, DIC, DMF/DCM (5:1 v/v), 12 h; (v) Reagent R, 2h.
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